Takeda and PvP Biologics have formed an agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby avoiding the painful symptoms and damage done in the small intestine from accidental gluten ingestion. PvP will conduct all research and development through phase 1 proof-of-principle studies per a pre-defined development plan.